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 ABSTRACT 
 
ANALYSIS AND QUANTITATION OF THE CROSS PRESENTATION OF 
TUMOR ANTIGENS USING THE HIV PROTEIN TRANSDUCTION 
DOMAIN TRANSACTIVATING REGULATORY PROTEIN (TAT) TO 
ALTER PRESENTATION 
 
By 
 
Jason Paul Aun 
 
 The hallmark of cross presentation is the immune system’s ability to 
present an exogenously derived antigen in the class I major histocompatibility 
complex (MHC) thus stimulating CD8+ TC cells.  Exogenously derived proteins 
are normally presented in a MHC class II with the cells stimulating activation of 
CD4+ TH cells which do not induce the desired cytotoxic effect.  Inducing cross 
presentation is important in cancer immunotherapies because the tumor antigens 
are presented in the same fashion as exogenous proteins which do not provide the 
necessary cytotoxic effect.  To stimulate a strong cytotoxic immune response, 
facilitating and optimizing cross presentation is paramount. 
 The purpose of this study was to analyze and quantitate the cross 
presentation of tumor antigens coupled with the protein transduction domain HIV-
TAT.  Protein transduction domains have the ability to enter a cell independent of 
any known receptor or endocytic activity.  Coupling of a modified version of 
HER2 with HIV-TAT transferred HER2 to the cytoplasm of the antigen 
presenting cells.  Labeling indicated that there was a slight increase in MHC class 
I expression using TAT-mHER2 compared to mHER2 alone.  We conclude that 
the results of this study warrant further investigation into optimizing this 
promising technology. 
 i 
  
 
 
 
 
 
 
 
 
 
Copyright by 
Jason Paul Aun 
2009 
 ii 
  
 
 
 
 
 
 
 
 
DEDICATION 
This thesis is dedicated to my Sito and to my Aunt Julie. 
Both lost their battles to cancer and it is my hope that in some small way this 
research will help others fight on. 
 iii 
 ACKNOWLEDGEMENTS 
 
 Completing this thesis would not have been possible without the help of 
several individuals.  First, I would like to thank Dr. Winn for his support and 
knowledge in helping with my research and for working with my weightlifting 
training schedule every semester.  I would also like to thank Drs. Becker and 
Rebers for taking time out of their busy schedules to be on my thesis committee.  
I owe tremendous gratitude to USA Weightlifting, the US Olympic Education 
Center, and NMU for giving me the chance to train and compete in a sport that I 
love and achieve my academic goals at the same time through the support of the 
B. J. Stupak Scholarship; this thesis would not have been possible without their 
help.  There are several people that have assisted or instructed me and I am 
grateful for their help and input:  Suzanne Dupler and Nathan Gazza for assisting 
me with the time consuming task of mHER2 production and Stephanie Humpula 
for helping me master the fluorescent microscope.  As for the arduous task of 
producing TAT-mHER2, I have the love of my life and wife-to-be Jessica Fides 
to thank.  Without her I would not have had any TAT-mHER2 for this study. 
 A multitude of students and faculty at NMU and the community of 
Marquette have made me feel like the Upper Peninsula is my second home.  I 
cannot thank all of you enough for making my time here so memorable. 
 And thank you so much to my family for all their support and love. 
 This thesis follows the format prescribed by The Publication Manual of 
the American Psychological Association and the Department of Biology. 
 iv 
 TABLE OF CONTENTS 
 
List of Figures ................................................................................................................... vii 
List of Abbreviations and Acronyms............................................................................... viii 
Introduction..........................................................................................................................1 
Major Histocompatibility Complexes and Antigen Presentation ............................1 
Cross Presentation of Antigens ...............................................................................6 
Protein Transduction Domains ..............................................................................12 
HER2 .....................................................................................................................13 
Current Approach ..................................................................................................16 
Materials and Methods.......................................................................................................19 
TAT-mHER2 and mHER2 Production .................................................................19 
Isolation of TAT-mHER2 and mHER2 Inclusion Bodies.....................................20 
Sample Quantification ...........................................................................................21 
TAT-mHER2 and mHER2 Protein Purification....................................................23 
Antigen Presentation .............................................................................................25 
Immunolocalization of HER2 Presentation in MHC Class I.................................26 
Results................................................................................................................................30 
Discussion..........................................................................................................................33 
References..........................................................................................................................38 
Appendix A:  Figures.........................................................................................................43 
 v 
 Appendix B:  Application to Use Vertebrate Animals ......................................................53 
 vi 
 LIST OF FIGURES 
 
 
 
Figure 1:  (a) PTD and protein ‘X’ complex, (b) protein ‘X’ being transported 
through the lipid bilayer by the PTD, and (c) refolding by HSP90 for 
reactivation (Schwarze et al., 2000) ......................................................................43 
 
Figure 2:  Plasmid pTriExSN-TAT-mHER2 containing PTD-TAT, extracellular 
and intracellular HER, and SIINFEKL.  The gene encoding TAT was 
inserted first with a linker followed by extracellular HER2 (HER2EC1/2), 
SIINFEKL, and intracellular HER2 (HER2IC1/4) ...............................................44 
 
Figure 3:  SDS-PAGE confirming presence of TAT-mHER2.  The left lane 
contains 10 µl of sample; the right lane contains 15 µl.........................................45 
 
Figure 4:  SDS-PAGE confirming the presence of the monoclonal antibody 25-
D1.16.  Left lane contains 5 µl of sample; the right lane contains 10 µl.  
The darker, thicker band is the immunoglobulin heavy chain; the two 
smaller bands are the two light chains (below the heavy chain) ...........................46 
 
Figure 5:  DAPI-stained APC with 0.15625 µM of TAT-mHER2 antigen (DAPI 
filter, magnification ×1000)...................................................................................47 
 
Figure 6:  TAT-mHER2 (0.15625 µM) expressed on APC cell surface bound to 
25-D1.16 mAb which is bound to biotin-conjugated rat anti-mouse 
immunoglobulin and stained with SAv-FITC; binding sites are intensely 
bright points (FITC filter; magnification ×1000).  Note:  the FITC-stained 
object in the upper-right corner is background interference..................................48 
 
Figure 7:  DAPI-stained APC and FITC-stained TAT-mHER2 (0.15625 µM) 
overlay (DAPI and FITC filters overlaid; magnification ×1000).  Note:  
the FITC-stained object in the upper-right corner is background 
interference ............................................................................................................49 
 
Figure 8:  Number of cells positive for mHER2 and TAT-mHER2 from antigen 
concentrations of 2.5 µM to 0 µM.  The asterisk denotes statistically a 
significant p-value .................................................................................................50 
 
Figure 9:  Number of positive signals per cell for mHER2 and TAT-mHER2 from 
antigen concentrations of 2.5 µM to 0 µM.  The asterisk denotes a 
statistically significant p-value ..............................................................................51 
 
Figure 10:  Average number of positive signals per cell for mHER2 and TAT-
mHER2 from antigen concentrations of 2.5 µM to 0 µM.....................................52 
 vii 
 LIST OF ABBREVIATIONS AND ACRONYMS 
 
 
 
° C – Degrees Celsius ........................................................................................................21 
 
µg – Microgram .................................................................................................................19 
 
µl – Microliter....................................................................................................................20 
 
µm – Micrometer ...............................................................................................................21 
 
µM – Micromolar...............................................................................................................25 
 
Antp – Drosophila Antennapedia Homeotic Transcription Factor ....................................12 
 
APC – Antigen Presenting Cell ...........................................................................................5 
 
ATP – Adenosine Triphosphate...........................................................................................2 
 
B Cell/Lymphocyte – Bone Marrow-Derived Cell/Lymphocyte (formerly Bursa 
of Fabricius-Derived Cell/Lymphocyte...................................................................5 
 
BCA – Bicinchoninic Acid Assay .....................................................................................25 
 
C – Carbon ...........................................................................................................................3 
 
C57BL/6 – Female Mouse 57 Black 6 (Denotes Original Breeding Stock)......................25 
 
CD4 – Cluster of Differentiation Molecule 4 ......................................................................1 
 
CD8 – Cluster of Differentiation Molecule 8 ......................................................................1 
 
CD28 – Cluster of Differentiation Molecule 28 ..................................................................7 
 
CD80 – Cluster of Differentiation Molecule 80 ..................................................................7 
 
CDR2 – Complementarity Determining Region 2.............................................................11 
 
CLIP – Class II Invariant Peptide ........................................................................................5 
 viii 
 CO2 – Carbon Dioxide .......................................................................................................26 
 
C-terminus – Carboxyl-terminus .........................................................................................3 
 
CTL – Cytotoxic T Lymphocyte........................................................................................11 
 
DAPI – 4’,6-Diamidino-2-Phenylindole............................................................................29 
 
DC – Dendritic Cell .............................................................................................................5 
 
DE3 – indicates that the host is a lysogen of λDE3 and carries a chromosomal 
copy of the T7 RNA polymerase gene under control of the lacUV5 
promoter allowing for production of protein from target genes cloned in 
pET vectors by induction with IPTG.....................................................................19 
 
dH2O – Distilled Water......................................................................................................22 
 
DNA – Deoxyribonucleic Acid .........................................................................................12 
 
EDTA – Ethylenediaminetetraacetic Acid.........................................................................24 
 
EGFR – Epidermal Growth Factor Receptor.....................................................................13 
 
ER – Endoplasmic Reticulum..............................................................................................4 
 
erbB – Epidermal Growth Factor Receptor .......................................................................13 
 
Erp57 – Endoplasmic Reticulum Protein 57........................................................................4 
 
FACS – Fluorescence-Activated Cell Sorting ...................................................................37 
 
FBS – Fetal Bovine Serum ................................................................................................27 
 
FITC – Fluorescein Isothiocyanate Conjugate ..................................................................28 
 
FPLC – Fast Protein Liquid Chromatography ...................................................................23 
 
g – Standard Gravity ..........................................................................................................21 
 
 ix 
 G1 – Gap 1 Phase ...............................................................................................................14 
 
GuHCl – Guanidine Hydrochloride ...................................................................................20 
 
H2-Kb – Haplotype 2-Nonclassical Gene K ......................................................................25 
 
HC – Histocompatibility ......................................................................................................9 
 
HCl – Hydrochloric Acid...................................................................................................27 
 
HCMV – Human Cytomegalovirus .....................................................................................8 
 
HER – Human Epidermal Growth Factor Receptor ..........................................................13 
 
HER2EC1/2 – HER2 Extracellular....................................................................................19 
 
HER2IC1/4 – HER2 Intracellular......................................................................................19 
 
HIV-1 TAT – Human Immunodeficiency Virus-1 Transactivator of Transcription  
 Protein....................................................................................................................12 
 
HLA-DM – Human Leukocyte Antigen-Nonclassical Class II MHC Molecule.................6 
 
HSP90 – Heat Shock Protein 90 ........................................................................................13 
 
HSV VP22 – Herpes Simplex Virus-1 DNA-Binding Protein Viral Protein 22 ...............12 
 
IFN-γ – Interferon-γ .............................................................................................................2 
 
IPTG – Isopropyl β-D-1-Thiogalactopyranoside...............................................................19 
 
kDa – Kilodalton................................................................................................................25 
 
LB – Luria-Bertani.............................................................................................................19 
 
LDS-PAGE – Lithium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis..................22 
 
LMP2 – Low Molecular Mass Polypeptide 2 ......................................................................2 
 x 
 LMP7 – Low Molecular Mass Polypeptide 7 ......................................................................2 
 
LMP10 – Low Molecular Mass Polypeptide 10 ..................................................................2 
 
M – Molar ..........................................................................................................................20 
 
mAb – Monoclonal Antibody ............................................................................................15 
 
MgCl2 – Magnesium Chloride ...........................................................................................20 
 
MHC – Major Histocompatibility Complex ........................................................................1 
 
mHER2 – Modified HER2 Construct Consisting of Extracellular HER2, 
SIINFEKL, and Intracellular HER2 ......................................................................18 
 
MIIC – Class II MHC-Rich Endosomes..............................................................................6 
 
ml – Milliliter.....................................................................................................................15 
 
mM – Millimolar................................................................................................................20 
 
MOPS – 3-Morpholinopropane-1-Sulfonic Acid ..............................................................22 
 
NaCl – Sodium Chloride....................................................................................................20 
 
NaOH – Sodium Hydroxide...............................................................................................27 
 
neu – Name Derived from a Neuroglioblastoma Murine Cell Line ..................................13 
 
Ni++ – Nickel Ion................................................................................................................23 
 
NiSO4 – Nickel Sulfate ......................................................................................................23 
 
nm – Nanometer.................................................................................................................20 
 
N-terminus – Amino-terminus.............................................................................................3 
 
OD – Optical Density.........................................................................................................20 
 xi 
 OVA – Ovalbumin.............................................................................................................11 
 
P-Value – Probability Value ..............................................................................................31 
 
PBS – Phosphate Buffered Saline......................................................................................24 
 
PCD – Paraneoplastic Cerebellar Degeneration ................................................................11 
 
pH – Potential of Hydrogen .................................................................................................5 
 
pLacI – Promoter lac Inducibility (Repressor) Gene.........................................................19 
 
PTD – Protein Transduction Domain ................................................................................12 
 
RBC – Red Blood Cell.......................................................................................................26 
 
RER – Rough Endoplasmic Reticulum................................................................................3 
 
RNA – Ribonucleic Acid ...................................................................................................20 
 
Rnase A – Ribonuclease A ................................................................................................12 
 
rpm – Revolutions per Minute ...........................................................................................26 
 
RPMI + 10% FBS – Roswell Park Memorial Institute Media with 10% Fetal 
Bovine Serum ........................................................................................................25 
 
S – Synthesis Phase............................................................................................................14 
 
Sav-FITC – Streptavidin-Fluorescein Isothiocyanate Conjugate ......................................28 
 
SDS-PAGE – Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis ..................21 
 
Sec61 – Secretory Pathway Protein 61 ................................................................................7 
 
SIINFEKL – Serine-Isoleucine-Isoleucine-Asparagine-Phenylalanine-Glutamate-
Lysine-Leucine ......................................................................................................17 
 
T Cell/Lymphocyte – Thymus-Derived Cell/Lymphocyte..................................................1 
 xii 
  xiii 
TAP – Transporter Associated with Antigen Processing ....................................................4 
 
TAP1 – Transporter 1, ATP-Binding Cassette, Sub-Family B............................................4 
 
TAP2 – Transporter 2, ATP-Binding Cassette, Sub-Family B............................................4 
 
TAT – Transactivator of Transcription Protein .................................................................12 
 
TAT-mHER2 – Transactivator of Transcription Protein Coupled with Modified 
HER2 Construct Consisting of Extracellular HER2, SIINFEKL, and 
Intracellular HER2 (also Denoted as TAT-EVI in Figure 2) ................................17 
 
TC Cell – T Cytotoxic Cell...................................................................................................1 
 
TH Cell – T Helper Cell .......................................................................................................1 
 
TKI – Tyrosine Kinase Inhibitor........................................................................................15 
 
US6 – Unspliced HCMV Glycoprotein 6 ............................................................................8 
 
UV – Ultraviolet ................................................................................................................24 
 
β2m – β2 Microglobulin........................................................................................................4 
 
β-gal – β-Galactosidase......................................................................................................12 
 
 INTRODUCTION 
 
Major Histocompatibility Complexes and Antigen Presentation 
 
 The class I major histocompatibility complex (MHC) is present on almost 
all nucleated cells and derives antigen from endogenous proteins produced within 
the cell.  Exceptions to this are immunologically privileged sites such as the 
anterior chamber of the eye, neurons in the brain, the cornea, testis, and the uterus 
(Goldsby, Kindt, & Osborne, 2000).  Cells in these privileged sites express the 
tumor necrosis factor Fas ligand on their cell surface, which binds to CD8+ TC 
cells expressing Fas receptor (Green &Ware, 1997).  This binding causes the 
CD8+ TC cells to undergo apoptosis thus avoiding tissue destruction by the 
immune system in these privileged sites (Green &Ware, 1997).  Additionally, 
there is very little expression of MHC class I molecules in these sites, further 
inhibiting CD8+ TC cell activity (Green &Ware, 1997).  Cornea transplants take 
advantage of this immunologic privilege allowing corneas from donors to be 
transplanted without rejection by the immune system (Green & Ware, 1997).  The 
CD8+ TC cell is a specialized T lymphocyte that originates in the bone marrow 
and matures in the thymus.  These cells are generally cytotoxic in nature and, in 
contrast to CD4+ TH cells, kill targeted cells outright rather than strictly activating 
a further immune response (Goldsby et al., 2000).  Both T cell populations 
express distinctive membrane molecules known as cluster of differentiation 
molecules (CD8 and CD4) acting as signal transducers to elicit the appropriate 
reaction with their respective MHC molecules.  T cytotoxic cells express CD8 
that interacts with MHC class I molecules and T helper cells express CD4 that 
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 interacts with MHC class II molecules.  The MHC class I derives antigens 
endogenously through the cytosolic pathway and the MHC class II derives 
antigens exogenously through the endocytic pathway.  To elicit a T cell immune 
response in either MHC class, extracellular antigens must first be internalized.   
After internalization of antigenic proteins through the plasma membrane by 
endocytosis from the extracellular fluid into the cytoplasm, internalized antigens 
are degraded by the proteasome (Ciechanover, 1994).  The proteasome is a large, 
cylindrical, multifunctional protease complex with a central channel.  This 
channel isolates the target protein for degradation, thereby preventing lysis of 
other proteins in the cytoplasm (Goldsby et al., 2000).  The proteins targeted for 
degradation by the proteasome often have the small protein ubiquitin attached to 
them (Ciechanover, 1998).  Ubiquitin’s primary function is to mark proteins for 
proteolysis through a complex cascade of enzymes (Ciechanover, 1998).  Proteins 
marked for degradation are typically short-lived (internalized antigens), 
misfolded, or have a dissociation of subunits (Hershko & Ciechanover, 1998).  
Once conjugated to ubiquitin, the proteasome can degrade the marked protein by 
cleaving peptide bonds between two or three different amino acid combinations in 
an ATP-dependent process generating a variety of peptides terminating with 
hydrophobic or basic residues (Ciechanover, 1998).  Two subunits of the 
proteasome, LMP2 and LMP7 are encoded within the MHC gene cluster and are 
induced by increased levels of the cytokine, interferon-γ (IFN-γ); another subunit, 
LMP10, is also induced by IFN-γ but it is not MHC encoded (Niedermann et al., 
1995).  The peptidase activities of proteasomes containing LMP2, LMP7, and 
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 LMP10 preferentially generate peptides with basic and/or hydrophobic residues 
that bind to MHC class I molecules (Niedermann et al., 1995).  These 
hydrophobic, and occasionally basic, residues that are part of the generated 
peptides act as anchor residues (at the carboxyl [C] terminal) to bind with the 
MHC class I molecule.  All peptides examined to date that bind to MHC class I 
molecules contain a carboxyl-terminal anchor (Goldsby et al., 2000).  These 
peptides also possess an anchor residue at position two or positions two and three 
at the N terminal residue and at the C terminal residue pointing into the cleft 
which are also important for binding (Lankat-Buttgereit & Tampé, 2002).  These 
antigenic peptides destined for interaction with the MHC class I molecule number 
only eight to 10 residues because the conformation of the peptide-binding cleft in 
MHC class I molecules is a closed groove (Goldsby et al., 2000).  Conversely, 
MHC class II molecules have an open peptide-binding cleft accommodating 
slightly longer peptides of 13-18 amino acids and do not require 
basic/hydrophobic residues for peptide binding (Goldsby et al., 2000).  These 
open and closed peptide-binding clefts arise from variations in the polymorphic 
residues, which are the amino acids that vary among different MHC alleles 
(Abbas & Lichtman, 2001).  These residues are located in and around the cleft 
which is composed of paired α-helices resting upon a floor made up of an eight-
stranded β-pleated sheet (Abbas & Lichtman, 2001). 
 The next challenge the cell must overcome is transporting the newly 
cleaved peptides to the rough endoplasmic reticulum (RER) where the MHC 
molecules are being synthesized by polyribosomes (Abbas & Lichtman, 2001).  
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 This is accomplished by the transporter associated with antigen processing (TAP), 
a member of the ATP-binding cassette transporter family, which is a membrane 
spanning heterodimer consisting of TAP1 and TAP2 (Abbas & Lichtman, 2001; 
Solheim, Carreno, & Hansen, 1997).  The TAP-transporter translocates peptides 
generated by the proteasome complex from the cytosol and actively pumps them 
into the lumen of the RER (Abbas & Lichtman, 2001; Lankat-Buttgereit & 
Tempé, 2002).  Major histocompatibility complex class I loading includes not 
only TAP but the components tapasin, calreticulin, Erp57, MHC class I heavy 
chain and MHC class I-β2 microglobulin (β2m) dimers (MHC class I light chain) 
(Ackerman, Kyritsis, Tampé, & Cresswell, 2003; Guermonprez, et al., 2003; 
Houde, et al., 2003).  The tapasin, calreticulin, and Erp57 function as chaperone 
proteins.  Tapasin brings TAP into proximity with the MHC class I molecule and 
allows it to acquire an antigenic peptide (Ortmann et al., 1997).  Calreticulin is 
responsible for the folding and peptide-loading of newly synthesized molecules of 
the MHC class I protein (Culina, Lauvau, Gubler, & van Endert, 2004).  The 
function of the resident ER thiol reductase Erp57 in MHC class I peptide 
assembly and loading is thought to contribute to the formation of disulfide bonds 
during the maturation of MHC class I chains (Lankat-Buttgereit & Tempé, 2002).  
Within the RER membrane, the newly synthesized MHC class I α chain associates 
with calnexin (a chaperone protein that assists in protein folding) until β2m binds 
to the α chain (Goldsby et al., 2000).  The MHC class I α chain-β2m heterodimer 
then binds to calreticulin and the TAP-associated protein tapasin (Solheim et al., 
1997).  The physical association of the α chain-β2-m heterodimer with the TAP 
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 protein promotes peptide capture by the class I molecule before the peptides are 
exposed to the luminal environment of the RER, where it has been demonstrated 
that unbound peptides are rapidly degraded (Goldsby et al., 2000).  As a result of 
binding, the MHC class I molecule becomes stable and can dissociate from the 
calreticulin and tapasin (Solheim et al., 1997).  The MHC class I α chain-β2-m 
heterodimer with its associated peptide fragment is transported from the RER to 
the plasma membrane by the Golgi apparatus, where it is expressed on the surface 
of the antigen-presenting cell (APC) and displayed to CD8+ TC cells (Goldsby et 
al., 2000). 
 The class II MHC is primarily presented on macrophages, dendritic cells 
(DCs), B lymphocytes, and endothelial cells which present antigens that have 
been internalized in phagocytic/endocytic vesicles (Abbas & Lichtman, 2001).  
Dendritic cells, which are professional antigen-presenting cells APCs, are the 
most important cells for initiating primary T cell responses and primarily present 
MHC class II (Abbas & Lichtman, 2001).  After internalization into the 
endosome, the antigen is degraded into peptide fragments by proteolytic enzyme 
digestion by moving through three increasingly acidic compartments: early 
endosomes (pH 6.0–6.5); late endosomes or endolysosomes (pH 5.0–6.0); and 
lysosomes (4.5–5.0) (Goldsby et al., 2000).  The mechanism by which 
internalized antigen moves from one endocytic compartment to the next has not 
been conclusively demonstrated (Goldsby et al., 2000).  The fragments are 
attached to MHC class II molecules which prior to coupling with the antigen 
peptide was bound to a class II invariant peptide (CLIP) in the RER; this invariant 
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 chain stabilizes the class II molecule before it has acquired the antigenic peptide 
(Goldsby et al., 2000).  To load the peptide onto the newly synthesized MHC 
class II molecule, the peptide exchange molecule HLA-DM facilitates the 
removal of CLIP from the binding cleft allowing peptides derived from the 
endocytosed protein to join in the endosomal compartment (possibly via the Golgi 
apparatus) (Abbas & Lichtman, 2001).  The endosome is an intracellular 
membrane-bound vesicle into which extracellular proteins are internalized during 
antigen processing (Abbas & Lichtman, 2001).  A subset of MHC class II-rich 
endosomes (MIIC) specialize in antigen processing and presentation by the class 
II MHC pathway (Abbas & Lichtman, 2001).  The antigen/MHC class II molecule 
complex is then transported via the Golgi apparatus to the cell surface for 
expression on the APC and displayed to CD4+ TH cells (Abbas & Lichtman, 
2001). 
Cross Presentation of Antigens 
 There is increasing evidence of a phenomenon known as cross 
presentation; that is exogenous proteins internalized by phagocytosis or 
pinocytosis, are presented in MHC class I molecules to CD8+ T cells (Saveanu & 
van Endert, 2005).  Cross presentation is a mechanism by which professional 
APCs (typically DCs) display exogenous and self-antigens of another cell (such 
as a tumor cell) and activate (or prime) a naïve CD8+ TC cell (Abbas & Lichtman, 
2001).  This occurs, for example, when a cancerous cell is ingested by a 
professional APC, and the tumor antigens are processed and presented in 
association with the MHC class I molecules, as opposed to MHC class II (Abbas 
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 & Lichtman, 2001).  The professional APC also provides costimulation to fully 
activate the T cell which involves the interaction of two proteins, CD80 on the 
APC and CD28 on the T cell (Abbas & Lichtman, 2001).  In vivo, DCs acquire 
endogenous antigens from infected cells in the periphery, and then migrate to the 
lymph nodes where they display antigenic peptides in association with MHC class 
I molecules (Groothuis & Neefjes, 2005).  The mechanism by which cross 
presentation occurs is poorly understood but recent research shows that it occurs 
in early phagosomes prior to the formation of the phagolysosome (Saveanu & van 
Endert, 2005).  The phagosome is an intracellular vacuole formed by the fusion of 
pseudopodia around a particle undergoing phagocytosis (Goldsby et al., 2000).  
The phagosome fuses with a lysosome to form a phagolysosome (Abbas & 
Lichtman, 2001).  Early macrophage phagosomes are formed mainly by ER 
membranes; these harbor Sec61 which has been shown to retrotransport ER 
proteins to the cytoplasm for degradation by the proteasome (Saveanu & van 
Endert, 2005; Gagnon, 2002).  The early phagosomes contain all the functional 
elements for TAP-dependent loading of MHC class I molecules (Saveanu & van 
Endert, 2005).  By completely separating the processing of exogenous antigens 
from that of endogenous ones, the existence of an autonomous ER-phagosome 
contributes to the efficiency of cross presentation of ER-mediated phagocytosed 
material (Saveanu & van Endert, 2005).  The uptake of particulate phagocytosed 
antigens that eventually become cross presented is much more efficient than the 
uptake of soluble antigens through pinocytosis (Kovacsovics-Bankowski, 
Benacerraf, & Rock, 1993; Saveanu & van Endert, 2005).  This was demonstrated 
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 by Ackerman et al. (2003), by incubating DCs with a soluble peptide fragment of 
US6 from the human cytomegalovirus (HCMV).  US6 is a HCMV-encoded type I 
glycoprotein peptide that inhibits peptide trafficking from the cytosol into the 
endoplasmic reticulum and subsequent peptide loading of MHC class I molecules 
(Kyritsis et al., 2001).  US6 inhibits peptide loading by inhibiting TAP function 
by binding to its luminal domain (Kyritsis et al., 2001).  The result of this 
inhibition was a reduction (up to 90%) of MHC class I molecules being displayed 
on the cell surface and inhibition of about 70% of the cellular TAP transporter 
pool leading to inhibition of endogenous antigen presentation (Kyritsis et al., 
2001).  This shows that US6 had to gain access to the complete perinuclear ER 
(Kyritsis et al., 2001).  To corroborate this, Kyritsis et al. (2001) incubated β2m-
deficient DCs with exogenous β2m and found that the exogenous β2m localizes 
rapidly to the perinuclear ER, associates with MHC class I heavy chains bearing 
ER-typical immature glycans, reconstitutes cell surface class I expression, and 
normalizes presentation of endogenous antigen (Kyritsis et al., 2001; Saveanu et 
al., 2005).  Both US6 and β2m do not access the ER of macrophages, due to the 
rapid degradation of endocytosed soluble proteins in macrophages (Saveanu et al., 
2005).  Limiting proteolytic activity in early endocytic vesicles is another 
requirement for efficient cross presentation—as demonstrated by macrophages, 
whose aggressive endocytic machinery focuses on pathogen destruction at the 
expense of cross presentation capacity (Saveanu et al., 2005). 
 Traditionally, the CD8+ paradigm states that CD8+ T cells can only 
recognize endogenously synthesized antigens, whereas CD4+ T cells recognize 
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 exogenous antigens (Larsson, Fonteneau, & Bhardwaj, 2001).  This paradigm 
failed to take into account the observation that immunity develops spontaneously 
to viruses that cannot infect professional APCs (such as Epstein-Barr virus), or to 
tumors and allografts that by themselves are poor APCs (Larsson et al., 2001).  In 
1976, Bevan showed that mice immunized with cells that express foreign minor 
histocompatibility (HC) antigens mounted an antigen-specific response that was 
restricted to self-class I MHC, demonstrating that exogenous pathways are 
important in the induction of CD8+ T cell responses (Larsson et al., 2001).  Minor 
HC antigens are proteins expressed outside of the MHC loci; these antigens are a 
contributing factor to graft rejection and are only recognized when they are 
presented in the context of self-MHC molecules unlike major histocompatibility 
antigens which are recognized directly by TH and TC cells, i.e. alloreactivity 
(Goldsby et al., 2000).  This study formed the basis of the postulate that antigens 
presented exogenously by donor cells to professional APCs were able to be 
presented on MHC class I molecules, i.e. cross presentation (Larsson et al., 2001).  
Several features were found from these cross presentation studies:  efficient cross 
presentation of antigen required bone-marrow-derived cells such as dendritic 
cells, diverse groups of antigens could access MHC class I by exogenous 
pathways, and in some cases, cross presentation was dependent upon the presence 
of TAP, suggesting that antigens have to access the cytoplasm of professional 
APCs to converge with conventional endogenous processing pathways (Larsson 
et al., 2001). 
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  It has been demonstrated that the components of the Sec61 complex, a 
translocon that forms a pore on the ER membrane, are also associated with 
phagosomes (Houde et al., 2003).  Sec61’s primary function is the co-
translational transfer of newly synthesized proteins into the RER (Lehner & 
Cresswell, 2004).  It has been hypothesized that proteins internalized through 
endocytosis are transferred from components of the Sec61 complex (Houde et al., 
2003).  After transferring from the endosome to the cytosol, the proteins would 
undergo ubiquitination and proteasomal degradation in the cytoplasm to generate 
the correct peptides for MHC class I loading (Houde et al., 2003).  These peptides 
would be transported into either the RER lumen through the TAP complex to 
form MHC class I-peptide complexes (Houde et al., 2003) or be transported back 
into the same phagosome from which they originated (Ackerman, Kyritsis, 
Tampé, & Cresswell, 2005; Guermonprez et al., 2003).  The MHC class I-peptide 
complexes formed in the RER would be transported to the cell surface through the 
secretory pathway, while the MHC class I-peptide complexes formed in the 
phagosomes would be transported to the cell surface through the membrane 
recycling machinery of endocytic/phagocytic organelles (Houde et al., 2003).  
After the antigen has been loaded onto the MHC class I molecule, it is then 
transported to the cell surface by the Golgi apparatus and then with an exocytic 
vesicle where it is finally expressed on the surface of the APC and displayed to 
CD8+ TC cells. 
 Albert et al. (1998) demonstrated that human DCs could phagocytose 
apoptotic influenza-infected monocytes and stimulate resting CD8+ T cells to 
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 develop into cytotoxic T lymphocytes (CTLs).  Dendritic cells pulsed with 
apoptotic tumor cells also primed tumor specific CTLs (Larsson et al., 2001).  
Additionally, studies showed that splenic DCs isolated after in vivo priming with 
ovalbumin (OVA)-loaded β2m-deficient splenocytes presented OVA antigens to 
OVA-restricted MHC class I CD8+ T cells (Larsson et al., 2001).  Cross 
presentation was TAP-dependent and restricted to the lymphoid CD8+ DC subset, 
even though myeloid CD8- DCs acquire antigens in vivo (den Haan, Lehar, & 
Bevan, 2000); CD8- DCs lack the co-receptor T cell accessory molecule CD8 
which is necessary for adhesion and signal transduction and thus are unable to 
cross present (Abbas & Lichtman, 2001; den Haan et al., 2000). 
 Studies have also been done on patients with paraneoplastic cerebellar 
degeneration (PCD) who also had limited underlying cancer (usually breast or 
ovarian) (Albert et al., 1998).  These patients also had antibodies toward 
complementarity determining region 2 (CDR2) antigen, which is normally 
expressed in immune-privileged sites (Albert et al., 1998).  Dendritic cells from 
these patients phagocytosed apoptotic tumor lines that expressed CDR2 and 
induced potent anti-CDR2 cytolysis from autologous T cells (Albert et al., 1998).  
These data suggest that, in PCD, cross presentation of tumor antigens by DCs 
provides the initial stimulus for CTLs in vivo (Larsson et al., 2001).  Several 
additional studies have confirmed that human DCs can cross present antigens 
from apoptotic tumor cells to CD8+ T cells (Larsson et al., 2001).  As evident by 
these studies, cross presentation might be essential for the generation of tumor 
immunity. 
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 Protein Transduction Domains 
 It has proven difficult to generate protective CD8+ T cell immunity to 
microbes, viruses, and cancer in humans with the current vaccine strategies 
employing peptides, plasmid DNA, subunit vaccines, and inactivated viruses 
(Larsson et al., 2001).  One possible reason is that delivery of exogenous antigens 
to DCs has not been optimized (Larsson et al., 2001).  Protein transduction 
domains (PTDs) have been described as short peptides that are able to penetrate 
the plasma membrane and this transducing property can be conferred upon other 
proteins when fused with the PTD (Ford, Souberbielle, Darling, & Farzaneh, 
2001).  Several PTDs have been described in recent years, the human 
immunodeficiency virus-1 transactivator of transcription protein (HIV-1 TAT) in 
1998, Drosophila Antennapedia homeotic transcription factor (Antp) in 1991, and 
herpes-simplex-virus-1 DNA-binding protein viral protein 22 (HSV VP22) in 
1997.  Neither the mechanism of protein transduction nor the biological function, 
if any, of PTDs is understood.  It has been demonstrated that transduction of 
PTDs does not occur through the normal receptor-, transporter-, endosome-, or 
absorptive-endocytosis-mediated processes (Schwarze, Hruska, & Dowdy, 2000).  
Treatment with drugs that inhibit cellular transport does not effect transduction 
(Del Gaizo Moore & Payne, 2004).  It has been demonstrated that linkage of 
molecules thought to be unable to penetrate the plasma membrane to PTDs 
confers the ability of the nonpermanent molecule to cross the membrane.  In 
1994, Fawell and colleagues demonstrated that large molecules such as β-
galactosidase (β-gal), horseradish peroxidase, Rnase A and domain III of 
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 Pseudomonas exotoxin A, when chemically cross-linked with TAT peptides were 
carried into cells in vitro.  Fawell et al. (1994) also demonstrated that β-gal 
activity was present in vivo in liver, kidney, and lung tissues as well as heart 
muscle fibers, the red pulp area of the spleen and even in the central nervous 
system indicating the TAT-β-gal fusion was able to cross the blood-brain barrier.  
One possible mechanism of entry proposed by Schwarze et al. (2000) involves 
direct penetration of the lipid bilayer caused by the localized positive charge of 
the PTD in which the momentum of the molecule drives the covalently attached 
‘cargo’ into the cytoplasm (Figure 1).  After transduction, the membrane 
energetics would then favor reformation of an intact lipid bilayer (Schwarze et al., 
2000).  The composition of PTDs have a moderate to high number of the basic 
amino acids arginine and lysine, which might be important for contact with the 
negatively charged inner face of the lipid bilayer (Schwarze et al., 2000).  
Schwarze’s group has suggested that denatured proteins may be transduced more 
efficiently than correctly folded proteins and then correctly refolded by 
chaperonins such as heat shock protein 90 (HSP90) also shown in Figure 1 (Ford 
et al., 2001; Schwarze et al., 2000). 
HER2 
 The human epidermal growth factor receptor (EGFR) family of tyrosine 
kinases consists of EGFR (HER1, erbB1), HER2 (erbB2, HER2/neu), HER3 
(erbB3) and HER4 (erbB4) (Slamon et al., 1989).  The human epidermal growth 
factor receptor HER2 was discovered in the early 1980s, when a mutationally 
activated form of its murine homolog neu was identified in a search for oncogenes 
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 in a carcinogen-induced rat tumorigenesis model (Moasser, 2007; Shih, Pady, 
Murray, & Weinberg, 1981; Slamon et al., 1989).  Its human homologue, HER2 
was simultaneously cloned and found to be amplified in a breast cancer cell line 
(King, Kraus, & Aaronson 1985; Moasser, 2007). The transforming potential of 
HER2 differs from that of neu in that HER2 is tumorigenic through 
overexpression while neu requires mutational activation (Moasser, 2007).  The 
relevance of HER2 to human cancer was established when it was discovered that 
approximately 25–30% of breast cancers have amplification and overexpression 
of HER2 and these cancers have worse biologic behavior and prognosis (Moasser, 
2007, Slamon et al., 1989).  The expressed protein, HER2, is a transmembrane 
protein that spans the cell membrane seven times and is approximately 500 amino 
acids in length.  Human epidermal growth factor receptor 2’s normal function is 
as a cell membrane surface-bound receptor tyrosine kinase involved with signal 
transduction leading to cell differentiation and growth (Olayioye, 2001).  Varied 
mechanisms for HER2 involvement in growth and differentiation have been 
proposed; however, no unified model has gained wide acceptance (Moasser, 
2007).  Three mechanistic models that have been proposed involve abnormalities 
in signaling and all involve the overexpression of HER2, either in homodimeric 
form or heterodimeric form coupled with either EGFR or HER3.  All three 
models point to a cascade effect of signals leading to any of the following:  G1/S 
cell cycle deregulation, loss of cellular polarity, dysregulation of cyclin D1 (a 
G1/S regulator), tumor invasion, tumor proliferation, and an increase in tumor 
metabolism and survival (Moasser, 2007). There are typically 25 to 50 copies of 
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 the HER2 gene in normal cells (Moasser, 2007).  In cancerous cells there can be a 
40- to 100-fold increase in HER2 expression, resulting in up to two million 
receptors expressed on the tumor cell surface (Lohrisch & Piccart, 2001; Moasser, 
2007; Venter, Tuzi, Kumar, & Gullick, 1987) illustrating the sheer number of 
aberrant signaling receptors. 
 Human epidermal growth factor receptor 2 is an attractive target for drug 
therapy because it is a cell membrane receptor-based protein allowing for 
antibody-based treatments to be utilized.  Several HER2-targeting therapeutic 
strategies have been utilized, most notably the humanized monoclonal antibody 
(mAb) trastuzumab.  Trastuzumab’s exact role in inhibiting HER2 tumors has not 
been fully elucidated (Moasser, 2007).  It is thought that trastuzumab acts on the 
extracellular segment of HER2 causing cellular arrest during the G1 phase of the 
cell cycle thereby reducing growth of the tumor (Kute et al., 2004).  Treating 
patients with early-stage HER2 positive tumors with trastuzumab in conjunction 
with chemotherapy (after tumor resection) has shown significant prolonging of 
disease-free survival and reduction of disease recurrence (Moasser, 2007).  
However, 70% of patients do not respond to trastuzumab and resistance to the 
drug develops rapidly in almost every patient treated (Kute et al., 2004).  Another 
negative aspect of trastuzumab treatment is cost; the full course of treatment is 
approximately $70,000 (Fleck, 2006). 
 Tyrosine kinase inhibitors (TKIs), such as imatinib, have shown promise 
as well for inhibiting HER2 positive tumor growth.  Potentially, TKIs have a 
desired advantage over monoclonal antibodies such as trastuzumab (Moasser, 
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 2007).  While trastuzumab is only able to bind to the extracellular segment of 
HER2 (being an antibody, which are cell-impermeable), TKIs are cell-permeable 
and can potentially inhibit the ligand-dependent and -independent kinase activity 
of HER2 residing within the intracellular domain (Moasser, 2007).  This strategy 
could be effective because kinase activity is essential for the oncogenic function 
of HER2 (Moasser, 2007).  Imatinib has shown positive treatment results in 
chronic myeloid leukemia and gastrointestinal stromal tumors and these successes 
led to treatment of HER2-positive tumors as well (Arteaga, 2003).  However, 
TKIs are not target-specific like antibodies and their off-target effects potentially 
limit their therapeutic value compared with antibodies (Moasser, 2007).  The 
development of HER2-specific TKIs has shown mixed to mediocre results as well 
(Moasser, 2007). 
 Trastuzumab and TKIs are two examples of treatments that have, at best, 
moderate potential.  Using PTDs is an attractive methodology because of their 
ability to penetrate virtually any cell, independent of a cell receptor.  This gives 
rise to the potential of using PTDs to elicit an immune response by coupling an 
antigen to the PTD that can be processed by dendritic cells and then presented to 
T cells.  This would potentially bypass any problems related to resistance, 
specificity, or toxicity. 
Current Approach 
 The current study takes advantage of PTD technology that may allow the 
transport of a protein directly into the cytosol and cause the protein to be 
processed by the endogenous antigen pathway and be expressed preferentially in a 
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 MHC class I molecule.  For this study, TAT PTD was used.  The transactivator of 
transcription protein has shown moderate promise in stimulation of T cells in vitro 
in previous studies conducted in our laboratory.  TAT will be coupled with a 
modified version of a human epidermal growth factor receptor protein, HER2.  
The modified construct was produced (linked with PTD-TAT) by cloning into a 
bacterial vector and consists of four components:  TAT, the extracellular 
component of HER2, the eight amino acid sequence SIINFEKL from ovalbumin 
(OVA257-264), and the intracellular component of HER2.  Collectively, this 
construct is denoted as TAT-mHER2 (m denotes modified). 
 One of the approaches that has been widely used in cancer immunotherapy 
has been to use antigens found on tumor cells to stimulate a cytotoxic immune 
response.  By isolating APCs and then exposing them to the specific antigen, 
either in its native or a modified form, the APCs on reinfusion into the patient 
may be able to stimulate a specific immune response directed at the tumor cells 
bearing those antigens.  However, one of the keys to immunotherapy is the ability 
to present antigens in MHC class I molecules and stimulate CD8+ T cytotoxic 
cells since the majority of proteins presented in MHC class I molecules are 
cytoplasmic and newly synthesized proteins which are degraded by the 
proteasome.  These peptides produced by the proteasome are transported into the 
ER by TAP.  Peptides derived from exogenous antigens such as would be the case 
if APCs were pulsed with soluble antigen and internalized by endocytosis are 
thought to be displayed primarily by MHC class II molecules and subsequently 
stimulate CD4+ T helper cells.  Our hypothesis is that using protein transduction 
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 domains, short peptides that are able to penetrate the plasma membrane, may 
confer their transducing property on other proteins when expressed as fusions 
with the PTD.  The advantage of this technology, over just pulsing APCs with 
soluble antigen, would be that transport of a protein antigen directly into the 
cytosol might allow the antigen to be processed by the endogenous antigen 
pathway and expressed preferentially in a MHC class I molecule. 
 Using mHER2 alone (soluble protein) and TAT-mHER2 (soluble protein 
fused to a PTD) we hypothesize that there will be a greater degree of MHC class I 
presentation as measured by immunofluorescence using a monoclonal antibody 
specific for presentation of our mHER2 in MHC class I molecules. 
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 MATERIALS AND METHODS 
TAT-mHER2 and mHER2 Production 
 A DNA sequence was designed for the TAT protein and the mHER2 
component which were then linked.  This sequence was ligated into a plasmid 
vector (pTriEX, Novagen) and then transformed to Escherichia coli cells (Figure 
2).  The vector (pTriEX) was first transformed into Novablue E. coli cells 
(Novagen) which produce high yields of plasmids.  The plasmids were isolated 
using a plasmid isolation kit from Qiagen and then the plasmids were used to 
transfect a second E. coli strain, Rosetta (DE3) pLacI cells.  These cells are 
engineered to express large quantities of repressor proteins from the LacI 
regulatory gene to allow for optimal cell growth.  After induction with isopropyl 
β-D-1-thiogalactopyranoside (IPTG), which binds to the repressor proteins 
leading to inactivation, large amounts of the target protein are produced by the lac 
operon.  The first gene inserted into the plasmid was TAT (with a linker) followed 
by extracellular HER2 (HER2EC1/2), SIINFEKL (amino acid residues 257-264 
of chicken ovalbumin), and intracellular HER2 (HER2IC1/4) (the mHER2 
plasmid construct did not have the TAT sequence).  Selection for transformed 
TAT-mHER2/mHER2 expressing cells was achieved by taking advantage of 
selective antibiotic resistance to carbenicillin and chloramphenicol.  These 
antibiotics were added to the initial culturing medium (carbenicillin 50 µg/ml, 
chloramphenicol 34 µg/ml), Luria-Bertani (LB) agar, to select for cells containing 
the recombinant DNA.  After culturing, a single colony was transferred to LB 
broth, also treated with carbenicillin and chloramphenicol (same concentrations), 
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 to allow the cells to proliferate overnight.  Expression of TAT-mHER2/mHER2 
protein was achieved by activating transcription of the lac operon with 1 mM 
IPTG which was added when optimal levels of E. coli growth were reached.  A 
spectrophotometer set to 600 nm absorbance was used to find the optical density 
(OD) of the broth.  When the OD600 reached an absorbance of 0.5 (equal to 5x105 
colony forming units/ml), with sterile LB broth used as the standard, the IPTG 
was added and incubated overnight.  The transcription of TAT-mHER2/mHER2 
resulted in the formation of cytoplasmic inclusion bodies. 
Isolation of TAT-mHER2 and mHER2 Inclusion Bodies 
 The inclusion bodies were isolated and then solubilized in denaturing 
conditions in 6 M guanidine hydrochloride (GuHCl).  After sufficient levels of E. 
coli growth were reached in the LB broth centrifugation was used to pellet the E. 
coli cells and the broth was removed by aspiration.  The resulting E. coli pellet 
was resuspended in a buffered solution of 50 mM Tris and 25% sucrose at a pH of 
8.0 (buffer A).  Buffer A was prepared from a stock buffer consisting of 20 mM 
Tris and 100 mM NaCl at a pH of 8.0; buffers B and C, discussed below, are 
made from this stock buffer as well.  After resuspension in buffer A, the E. coli 
cells were then lysed with a buffered 8.0 pH lysing solution consisting of 1% 
deoxycholate, 1% Triton X-100 (a nonionic surfactant), 0.3 mg/ml Sigma 
lysozyme, and 1 mM Calbiochem Protease Inhibitor Cocktail Set III (buffer B).  
After mixing the E. coli cells in the suspension of buffers A and B for 15 minutes, 
a solution of 1 mM MgCl2 and 0.02 µl/ml of benzonase endonuclease was added 
to the suspension to remove all DNA and RNA components and reduce viscosity.  
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 The lysates were then centrifuged at 6,800 x g for 10 minutes at 4° C in a Sorvall 
RC-5B centrifuge using the SLA-3000 rotor to pellet the lysates; the supernatant 
(buffer A and buffer B) was removed by aspiration and discarded.  The lysate 
pellet was resuspended in a buffered solution consisting of 0.5% Triton X-100 
(buffer C), centrifuged again at 6,800 x g for 10 minutes at 4° C, and the 
supernatant was aspirated; this was repeated two more times.  The pellet was then 
resuspended in stock buffer followed by centrifugation at 6,800 x g for 10 minutes 
at 4° C and then the supernatant aspirated again.  The pellet was resuspended 
again in stock buffer, transferred to an Oak Ridge tube and centrifuged at 11,000 
x g for 10 minutes at 4° C.  The supernatant was aspirated and discarded leaving a 
pellet consisting of purified inclusion bodies.  The purified pellet of inclusion 
bodies was resuspended in an 8.0 pH solubilization buffer consisting of 20 mM 
Tris, 6 M GuHCl, 0.5 M NaCl, 10 mM imidazole, and 5 mM β-mercaptoethanol.  
The inclusion bodies were placed on a rotary mixer for 55 minutes at room 
temperature to ensure pellet resuspension.  The Oak Ridge tube containing the 
suspension was then centrifuged at 9,800 x g for 10 minutes at 4° C to pellet the 
non-protein components of the suspension.  The remaining supernatant, consisting 
of the solubilized inclusion bodies (protein), was sterile vacuum filtered through a 
0.22 µm cellulose acetate filter to remove any additional particulates that did not 
pellet and potential bacterial contaminants. 
Sample Quantification 
 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
confirmed the presence of TAT-mHER2/mHER2 protein (Figure 3) using 
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 Invitrogen Pre-Cast NuPAGE Novex 4-12% Bis-Tris Gels.  One hundred 
microliters of the TAT-mHER2/mHER2 protein samples (from the inclusion body 
isolation above), both in volumes of approximately 15 ml after sterile vacuum 
filtration, were prepared for SDS-PAGE first by suspending in 100% ethanol to 
take the protein out of solution from the 6 M GuHCl.  The sample was cooled at -
20° C for 10 minutes prior to micro-centrifugation for eight minutes at 4° C to 
pellet the protein.  After removal of the supernatant, 90% ethanol was added, 
vortexed briefly to resuspend the pellet, and then cooled again at -20° C for 5 
minutes prior to micro-centrifugation at 16,000 x g for eight minutes at 4° C.  The 
supernatant was removed, the pellet allowed to air-dry and then resuspended in 
distilled water (dH2O), 500 mM Invitrogen dithiothreitol, and 4 X lithium dodecyl 
sulfate PAGE (LDS-PAGE) buffer (Invitrogen).  Two molecular weight standards 
were used to verify that the electrophoresis had run properly and to find the 
appropriate weight as well as presence of the TAT-mHER2/mHER2 proteins.  
Invitrogen SeeBlue® Plus2 Pre-Stained Standard allowed visualization of weight 
ranges during electrophoresis and Invitrogen Mark12™ Unstained Standard 
allowed close estimation of the TAT-mHER2/mHER2 molecular weight.  The 
pre-cast gels were loaded with TAT-mHER2/mHER2 samples and both molecular 
weight markers and run completely submerged in an Invitrogen Novex Mini-Cell 
gel box with NuPAGE MOPS SDS Running Buffer (Invitrogen) and NuPAGE 
Antioxidant (Invitrogen) for 54 minutes at 200 volts.  After completion of 
electrophoresis, the pre-cast gel was removed from the gel box, opened, rinsed 
with dH2O, and placed into a staining tray to stain overnight in Invitrogen 
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 SimplyBlue™ SafeStain on an agitator.  After staining, the gel was de-stained 
overnight with dH2O then prepared for permanent archiving and easy observation 
of results by placing the gel between two sheets of cellophane soaked in 
Invitrogen Gel-Dry Solution and allowed to dry over night using an Invitrogen 
DryEase Gel Drying System. 
TAT-mHER2 and mHER2 Protein Purification 
 TAT-mHER2 and mHER2 protein purification was achieved by protein 
capture on a nickel ion (Ni++) chelating column, through Pharmacia Fast Protein 
Liquid Chromatography (FPLC).  The plasmid transfected to the E. coli genome 
carried a sequence to code for six histidine amino acids to act as a tag for 
chelating with nickel sulfate (NiSO4).  An GE Healthcare HiTrap™ 5 ml 
Chelating HP Column was loaded with 100 mM of NiSO4 and then washed with 
solubilization buffer to remove any excess NiSO4.  Imidazole in the solubilization 
buffer (20 mM Tris, 6 M GuHCl, 0.5 M NaCl, 10 mM imidazole, 5 mM β-
mercaptoethanol, pH 8.0) was used to elute non-specific proteins (less than six 
histidine tags) off the column into 20 mM imidazole fractions.  The 20 mM 
imidazole was the result of the solubilization buffer (10 mM imidazole) mixed 
with an elution buffer consisting of 20 mM Tris, 6 M GuHCl, 0.5 M NaCl, and 
300 mM imidazole at pH of 8.0.  Specific proteins (six histidine tags) were eluted 
off the column using elution buffer alone.  Next, the protein solubilized in the 
solubilization buffer was loaded onto the column.  The histidine tags present on 
the protein allowed chelation with the NiSO4, forming a protein-Ni++ complex 
bound to the column.  These Ni++-bound proteins were eluted off the FPLC 
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 column with imidazole.  The non-specific proteins were eluted off the column 
first in 20 mM imidazole fractions collected in 10 ml increments.  Determining 
when to collect the appropriate 20 mM imidazole fraction was achieved when the 
UV spectrophotometer on the FPLC showed a constant, mid-range plateau as the 
elution buffer moved through the column.  When the UV spectrometer showed a 
significant increase in absorbance, 1 ml fractions were collected which consisted 
of 300 mM imidazole and these fractions consisted of the specifically-bound 
target protein (six histidine tags).  Fraction collection was stopped when the UV 
peaks began to decline.  All the 1 ml fractions were combined and 0.5 M 
ethylenediaminetetraacetic acid (EDTA) was added. 
 The purified TAT-mHER2/mHER2 protein was resuspended in 20 mM 
Tris, 6 M GuHCl, 0.5 M NaCl, 2 mM EDTA and was injected into a Pierce Slide-
A-Lyzer dialysis cassette then dialyzed against a refolding/renaturation buffer 
consisting of 100 mM Tris, 0.5 M arginine, 2 mM EDTA, 2.5 mM reduced 
glutathione, and 0.5 mM oxidized glutathione at a pH of 8.0 to remove the GuHCl 
and to refold and renature the protein.  This was done for 12 hours at 4° C on a 
stir plate.  After 12 hours, the buffer was replaced with fresh 
refolding/renaturation buffer and dialyzed for another 12 hours at 4° C on a stir 
plate.  The refolding/renaturation buffer was then replaced with phosphate 
buffered saline (PBS) and dialyzed again for 12 hours and repeated once more 
with fresh PBS for another 12 hours, both at 4° C on a stir plate.  The refolded 
and renatured protein, now suspended in PBS, was suitable for in vitro use.  
Lastly, the protein was concentrated through ultrafiltration using an Amicon 
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 Ultra-15 Centrifugal Filter Device (10,000 kDa nominal molecular weight limit).  
The concentration of TAT-mHER2/mHER2 protein was determined by 
bicinchoninic acid assay (BCA).  A Molecular Devices SpectraMax Plus 
Spectrophotometer (absorbance at 570 nm) operated by SOFTmax Pro 3.1.1 
software was used to read the BCA assay absorbance results. 
Antigen Presentation 
 Delivery of the TAT-mHER2/mHER2 was achieved by introducing the 
antigen to APCs cultured in vitro from murine (Mus musculus) spleen.  Five 
different antigen concentrations were used, 2.5 µM, 1.25 µM, 0.625 µM,     
0.3125 µM, and 0.15625 µM, as well as a PBS control.  Female H2-Kb positive 
C57BL/6 mouse spleens were used for the procedure.  Spleen procurement began 
with cervical dislocation of the mouse followed by wetting of the mouse with 
70% ethanol.  To remove the spleen the skin was first lifted and cut with scissors 
to expose the abdominal muscle which was cut away as well to expose the spleen 
(appears dark-red in color and is long and thin in shape).  The spleen was excised 
from the mouse and had all the connective tissue removed.  Next, the spleen was 
placed into a Petri plate with Roswell Park Memorial Institute media with 10 ml 
of 10% fetal bovine serum (RPMI + 10% FBS).  Using the frosted ends of two 
glass microscope slides, cleaned with 70% ethanol and rinsed with PBS, the 
mouse spleen was ground into a thin pulp into the RPMI + 10% FBS.  The ground 
spleen and the RPMI + 10% FBS were then aspirated into a 15 ml centrifuge tube.  
An additional 5 ml of RPMI + 10% FBS was added to the Petri dish and rinsed on 
the slides to collect any remaining splenocytes; this was also added to the 15 ml 
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 centrifuge tube.  The splenocytes were centrifuged at 1250 rpm for 5 minutes to 
pellet the cells.  The RPMI + 10% FBS was aspirated and 1 ml Sigma red blood 
cell (RBC) lysing buffer was added to lyse any RBCs.  After one minute, 14 ml of 
RPMI + 10% FBS was added and the splenocytes were centrifuged again at 1250 
rpm for 5 minutes to pellet the cells.  Following centrifugation, the RPMI + 10% 
FBS was aspirated and 7 ml of fresh RPMI + 10% FBS was added to resuspend 
the splenocytes.  The 7 ml RPMI + 10% FBS/splenocyte suspension was 
transferred to a 70 ml, 25 cm2 cell culture flask and incubated for two to four 
hours at 37° C, 5% CO2.  After incubating, all RPMI + 10% FBS media and non-
adherent cells were removed by aspiration.  The flask was scraped to harvest the 
adherent cells (antigen presenting cells) and 12 ml of fresh RPMI + 10% FBS was 
added to resuspend the dendritic cells for aliquoting.  A 24-well plate was 
prepared with 12 round coverslips (sterilized with 70% ethanol and rinsed with 
PBS) placed inside 12 wells where 1 ml of the RPMI + 10% FBS/dendritic cell 
suspension was aliquoted into each well and allowed to incubate for two hours at 
37° C, 5% CO2. 
Immunolocalization of HER2 Presentation in MHC Class I 
 To determine the MHC class I expression levels of the TAT-mHER2 
antigen, a modified version of a direct enzyme-linked immunoabsorbent assay to 
determine immunolocalization was employed and an Olympus BX51 Fluorescent 
Microscope was used to visualize the fluorescence of the labeled antigen.  The 
antigen presenting cells obtained from the spleens of female H2-Kb positive 
C57BL/6 mice were grown on untreated glass cover slips placed inside 24-well 
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 plates.  After incubating for two hours in RPMI + 10% FBS media, the non-
adherent cells were aspirated and 1 ml new media was added along with TAT-
mHER2 acting as the antigen for the splenocyte APCs to uptake.  Additionally, 
mHER2 (not cross-linked with TAT) were also tested serving as a comparative 
antigen in separate wells.  Both antigens were added to each successive well in 25 
µl volumes of decreasing concentrations (diluted in PBS) with each successive 
dilution being half the concentration of the previous dilution, i.e. 2.5 µM, 1.25 
µM, 0.625 µM, 0.3125 µM, and 0.15625 µM, as well as a PBS control.  After the 
addition of the antigen, the cells were incubated overnight to allow for antigen 
processing.  Next, the media was aspirated and the cells fixed with 1 ml of 4% 
paraformaldehyde for 10 minutes, aspirated, and rinsed twice with PBS.  The 4% 
paraformaldehyde solution was prepared immediately prior to use by adding 0.6 
grams of paraformaldehyde, 12 ml of dH2O, and 5 ml of 1 M NaOH to a beaker 
which was heated to 70°C and stirred until the paraformaldehyde solubilized 
(Doyle, 1996).  The solution was cooled to 25°C, the volume was adjusted to 13.5 
ml with dH2O, and 1.5 ml of 10 X PBS was added to bring the final volume to 15 
ml (Doyle, 1996).  The pH was adjusted to 7.4 using drops of 10% HCl and the 
solution was sterile vacuum filtered through a 0.22 µm cellulose acetate filter 
(Doyle, 1996).  Twenty five microliters of goat serum were then added as a 
blocking agent, allowed to incubate for five minutes at 37° C, 5% CO2, aspirated, 
and washed twice with BD Pharmingen Stain Buffer with 2% FBS (Dulbecco’s 
Phosphate-Buffered Saline with 2% fetal bovine serum, 0.09% sodium azide, pH 
7.4); this blocking step was repeated three times.  After blocking, 25 µl of the 
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 primary antibody 25-D1.16, diluted to 1:100 in BD Pharmingen Stain Buffer with 
2% FBS, was added to each well and incubated for 60 minutes at 37° C, 5% CO2 
and then washed three times over five minutes with PharMingen Stain Buffer.   
 This murine monoclonal antibody was produced by a hybridoma cell line 
provided by Angel Porgador and Jonathan Yewdell and it recognizes MHC class I 
molecules complexed with the amino acid sequence SIINFEKL (OVA257-264) 
which TAT-mHER2 and mHER2 possess (Figure 4).  The 25-D1.16 hybridoma 
cell line was originally cultured in Dulbecco’s Modified Eagle Medium with 10% 
heat inactivated fetal calf serum and then Iscove’s Modified Dulbecco’s Medium 
with 10% FBS for antibody production.  This hybridoma cell line produced 
copious amounts of 25-D1.16 antibody. 
 A secondary antibody, AbCam biotin-conjugated rat anti-mouse 
immunoglobulin, λ2 and λ3 light chain mAb (2B6ab) was then added to bind with 
the 25-D1.16 primary antibody (also diluted in Pharmingen Stain Buffer, but at 
double the concentration, 1:50) and allowed to incubate for an additional 60 
minutes at 37° C, 5% CO2.  After washing three times over five minutes using 
PharMingen Stain Buffer, 25 µl of PharMingen Streptavidin-Fluorescein 
Isothiocyanate Conjugate (Sav-FITC or simply FITC) was added in a 
concentration that was double the concentration of the secondary antibody, 1:25, 
to conjugate to the biotin complexed with the secondary antibodies for 
immunofluorescence.  This step and all subsequent steps were performed in low-
light conditions to preserve fluorescence.  The cover slips within the wells were 
then mounted on slides and counter stained with Vector Vectashield Mounting 
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 Medium for fluorescence with 4’,6-diamidino-2-phenylindole (DAPI) prior to 
analysis with the fluorescent microscope.  Splenocytes expressing TAT-mHER2 
or mHER2 displayed green fluorescent points on the cell surface (Figure 5) under 
the FITC filter and non-expressing cells were invisible or faintly colored.  Three 
images were taken of each cell (using Applied Imaging fluorescent imaging 
software) under both the DAPI and FITC filters as well as an overlay of both 
pictures combined (Figures 5, 6, and 7).  It is interesting to note that the 
concentration of TAT-mHER2 in these figures is at 0.15625 µM.  Diluting each 
antigen was done to determine when each reached a point of no longer being 
recognized by the primary antibody 25-D1.16.  TAT-mHER2 and mHER2 were 
diluted as such:  2.5 µM, 1.25 µM, 0.625 µM, 0.3125 µM, 0.15625 µM, and a 
PBS control. 
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 RESULTS 
 To compare the expression level of both antigens (mHER2 and TAT-
mHER2), cells counts were taken of the number of positive cells, cells showing 
FITC signaling, and the number of positive signals in each cell.  The number of 
positive signals per cell was determined by counting individual FITC signals on a 
positive cell; for example, Figure 6 depicts nine positive FITC signals on that 
particular cell.  The number of positive signals in each cell was divided by the 
number of positive cells resulting in the average number of positives per cell.  
These counts were taken at each concentration, including the mHER2 and TAT-
mHER2 PBS controls.  Only cells displaying the processed antigen in MHC class 
I were detectable in this assay due to the specificity of the 25-D1.16 mAb.  The 
eight amino acid SIINFEKL sequence inserted between the intracellular and 
extracellular HER2 components must undergo antigen processing by the APCs in 
order to be recognized by the 25-D1.16 mAb.  Any antigen that did not undergo 
cellular uptake and processing but was adhering APC’s outer-membrane would 
not elicit any antigen/mAb interaction. 
 At every concentration level, except 0.15625 µM, there were more 
positive TAT-mHER2 cells than mHER2 cells.  Comparison of paired groups 
showed a significant difference for TAT-mHER2-treated cells at 1.25 µM (Figure 
8).  The number of positive signals from the TAT-mHER2-treated cells was also 
higher than the mHER2-treated cells at every concentration level however the 
differences were not significant except at 1.25 µM and 0.625 µM (Figures 8 and 
9).  An asterisk denotes the statistically significant 1.25 µM and 0.625 µM TAT-
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 mHER2 concentrations in Figures 8 and 9.  The PBS controls (which were not 
treated with either TAT-mHER2 or mHER2) also showed some low level positive 
signals, but these were attributed to nonspecific background staining (Figures 8 
and 9).  Interestingly, the average number of positives per cell was higher for 
mHER2 at all concentrations except at 0.625 µM and 0.3125 µM indicating that 
while less cells displayed mHER2, those that did displayed it at higher levels 
(Figure 10).  These two concentration levels could show a possible optimal 
concentration level for TAT-mHER2 cell delivery. 
 A t-test for the two correlated samples (mHER2 versus TAT-mHER2) at 
each concentration was performed on both the number of positive cells and 
positives per cell to determine if the sum of the change between the two groups 
differed significantly from zero.  The t-tests for these data revealed p-values that 
were insignificant at every concentration except at 1.25 µM (positive cells) and 
0.625 µM (positives per cell): 
        Concentration      p-value (Positive Cells) 
2.5 µM  0.16647 
1.25 µM  0.00097 
0.625 µM  0.10891 
0.3125 µM  0.72527 
0.15625 µM  0.31934 
PBS Controls  0.34791 
        Concentration      p-value (Positives per Cell) 
2.5 µM  0.56511 
1.25 µM  0.07529 
0.625 µM  0.00717 
0.3125 µM  0.72930 
0.15625 µM  0.55242 
PBS Controls  0.33247 
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 Additionally, three other concentration levels showed p-values that approached a 
p-value of 0.05:  2.5 µM and 0.625 µM for positive cells and 1.25 µM for 
positives per cell.  Both the 1.25 µM and 0.625 µM concentrations showed a 
correlation between the positive cells and positives per cell counts. 
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 DISCUSSION 
 Eliciting a cytotoxic immune response to cancer antigens, which are 
essentially self-antigens, has traditionally been a major obstacle, due to the APCs 
presenting these antigens in an MHC class II.  The subsequent activation of CD4+ 
TH cells typically leads to the release of cytokines which in turn activate B 
lymphocytes, macrophages, and CD8+ TC cells.  However, the CD8+ TC cells 
cannot induce apoptosis due to the lack of costimulatory signaling from the target 
cell which leads to clonal anergy (Goldsby et al., 2000).  This signal is triggered 
by the interaction of CD80 on the APC with CD28 present on either CD4+ TH or 
CD8+ TC cells. 
 Another factor involved with this ineffective immune response is down-
regulation of MHC class I expression on tumor cells which may allow the tumor 
to escape CTL-mediated recognition (Goldsby et al., 2000).  The immune 
response may play a role in selecting tumor cells expressing lower levels of MHC 
class I molecules by preferentially eliminating those cells expressing high levels 
of MHC class I molecules and, with time, malignant tumor cells may express 
progressively fewer MHC molecules and thus escape CTL-mediated destruction 
(Goldsby et al., 2000).  To compound this phenomenon, most tumors grow 
rapidly and it quickly becomes futile for the immune system to target and kill 
every tumor cell.  Additionally, tumors can evolve to evade immune responses 
either by failing to express a tumor antigen on its MHC molecule, having an 
MHC mutation prevent MHC expression, or through production of 
immunosuppressive cytokines (Abbas & Lichtman, 2001). 
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  Cross presentation is the immune system’s response to these tumor 
evasion mechanisms.  When an APC ingests a tumor cell, cross presentation 
occasionally occurs leading to a CD8+ TC cell interaction, CD8+ TC cell 
differentiation into a CTL, and finally apoptosis of tumor cells.  The intracellular 
mechanisms of cross-presentation are still unclear, but seem to involve 
specialized subcellular compartments bearing characteristics of both the 
endoplasmic reticulum and the endosome (Guermonprez et al., 2003).  Taking 
advantage of this ability possessed by APCs allows the immune system to keep 
certain viruses and tumors in check even though these antigens would normally be 
presented in an endogenous manner.  Increasing cross presentation in APCs and 
increasing the number of cross presenting APCs in general through the use of 
PTDs has been attempted by a number of researchers.  The attractive feature of 
PTDs is the ability to enter a cell independent of any known receptor or endocytic 
activity.  Add to this that PTDs can be coupled to other, much larger molecules 
and not lose their transducing properties presents a potential boon to 
immunotherapy research. 
 Kim et al. (1997) and Shibagaki and Udey (2002) were able to 
demonstrate the abilities of HIV-TAT PTD to induce the MHC class I pathway 
and thus showing an alternative to traditional methods of DC pulsing.  Recent 
research by Tanaka, Dowdy, Linehan, Eberlein, and Goedegebuure (2003) and 
Viehl et al. (2005) demonstrated successful protein transduction of cancer 
antigens coupled with the HIV-TAT PTD and a subsequent induction of antigen-
specific CTLs.  All four studies demonstrated the efficiency by which proteins 
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 could be introduced into the MHC class I pathway over the traditional use of 
tumor cell preparations such as tumor lysates and apoptotic tumor cells or DC-
tumor cell fusions (Tanaka et al., 2003).  Other methods involving DNA, RNA, or 
viral vectors containing tumor antigen genes were also not as efficient as PTD 
transfer (Tanaka et al., 2003). 
 Vaccine production has continually been stymied because of MHC class II 
elicitation in lieu of MHC class I.  In all likelihood inducing just a MHC class I 
response would be virtually impossible, however Viehl et al. (2005) demonstrated 
that TAT coupled with mammaglobin (a breast cancer-associated protein) 
transduced dendritic cells induces both CD4 and CD8 mammaglobin-specific T 
cells.  This scenario shows great promise that a vaccine could be developed using 
this technology.  Effective antitumor immune responses are thought to require the 
contribution of both CD4+ and CD8+ T cells, making protein transduction of 
tumor antigens a viable strategy because of HIV-TAT’s ability to cross the cell 
membrane of most mammals (Schwarze et al., 2000; Viehl et al., 2005). 
 The objective for this study was to analyze and quantitate the cross 
presentation of HER2 antigens coupled with the PTD HIV-TAT compared to 
HER2 alone.  Our approach entailed using HIV-TAT to transport exogenous 
proteins to the cytosol where they would enter the endogenous pathway.  
Immunolocalization analysis was conducted using the mAb 25-D1.16.  This mAb 
is specific for the peptide sequence SIINFEKL, the eight amino acid residues of 
chicken ovalbumin (residues 257-264), found between the extracellular HER2 and 
intracellular HER2 components of our TAT-mHER2 and mHER2 proteins and 
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 labeling with mAb 25-D1.16 was used to display in an MHC class I molecule on 
murine splenic APCs.  Labeling indicated that there was an increase in MHC class 
I expression using TAT-mHER2 compared to mHER2 and that increase was 
significant using 1.25 µM and 0.625 µM antigen concentrations (Figures 8 and 9).  
We expected to see greater MHC class I presentation following incubation with 
TAT-mHER2; while greater presentation was seen, the increased presentation was 
not as robust as expected. 
 While our hypothesis was not fully supported by the results of this study, 
similar studies conducted previously by Tanaka et al. (2003) and Viehl et al. 
(2005) showed more favorable results thus warranting further investigation.  
Several factors may have contributed to our results not supporting our hypothesis:  
the particular TAT-mHER2 sample used in this study may not have been fully 
functional; if the TAT-mHER2 was functional, there may have been no 
ubiquitination of the protein and therefore no antigen processing through the 
endocytic pathway; preparing the splenocytes for in vitro analysis may have 
placed too much stress on the murine splenic dendritic cells resulting in a 
decreased ability to process antigens; the assay developed for this study may not 
have been sensitive enough.  Additionally, determining if the antigen was 
delivered into the cell or if the antigen just merely coated the cell surface, with no 
uptake, requires further study.  Further, whether or not the antigen induced an 
immune response and if the actual cellular uptake of the antigen was through 
protein transduction need evaluation.  Analyzing and quantitation of the cross 
presentation of HER2 tumor antigens could be optimized through the use of 
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 fluorescence-activated cell sorting (FACS) or green fluorescent protein.  Using 
both of these methods would allow the assay of live cells.  Improving antigen 
delivery could potentially be improved through adding another PTD protein to the 
antigen (i.e. TAT-TAT-mHER2 or TAT-mHER2-TAT).  Accomplishing this 
construct may require the use of cosmids, bacterial artificial chromosomes, or 
yeast artificial chromosomes to accommodate the larger genetic sequence.  
Additionally, determining if there is any specificity to PTD/cargo protein 
combinations might allow future study into optimizing antigen uptake.  
Expanding this study to an in vivo model may also improve more efficient TAT-
mHER2 delivery and antigen presentation. 
 Continuing and expanding research into PTD biotechnology, particularly 
in regards to immunotherapy and the mechanistic means by which PTDs gain cell 
entry, could produce great gains in our ability to present cancer associated 
antigens to the immune system and may eventually lead to improved cancer 
patient outcomes. 
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 APPENDIX A 
 
 
 
FIGURES 
 
 
 
 
 
Figure 1:  (a) PTD and protein ‘X’ complex, (b) protein ‘X’ being transported 
through the lipid bilayer by the PTD, and (c) refolding by HSP90 for reactivation 
(Schwarze et al., 2000). 
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Figure 2:  Plasmid pTriExSN-TAT-mHER2 containing PTD-TAT, extracellular 
and intracellular HER, and SIINFEKL.  The gene encoding TAT was inserted 
first with a linker followed by extracellular HER2 (HER2EC1/2), SIINFEKL, and 
intracellular HER2 (HER2IC1/4). 
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             58.8 kDa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  SDS-PAGE confirming presence of TAT-mHER2.  The left lane 
contains 10 µl of sample; the right lane contains 15 µl. 
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Figure 4:  SDS-PAGE confirming the presence of the monoclonal antibody 25-
D1.16.  Left lane contains 5 µl of sample; the right lane contains 10 µl.  The 
darker, thicker band is the immunoglobulin heavy chain; the two smaller bands 
are the two light chains (below the heavy chain).
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Figure 5:  DAPI-stained APC with 0.15625 µM of TAT-mHER2 antigen (DAPI 
filter, magnification ×1000). 
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Figure 6:  TAT-mHER2 (0.15625 µM) expressed on APC cell surface bound to 
25-D1.16 mAb which is bound to biotin-conjugated rat anti-mouse 
immunoglobulin and stained with SAv-FITC; binding sites are intensely bright 
points (FITC filter; magnification ×1000).  Note:  the FITC-stained object in the 
upper-right corner is background interference. 
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Figure 7:  DAPI-stained APC and FITC-stained TAT-mHER2 (0.15625 µM) 
overlay (DAPI and FITC filters overlaid; magnification ×1000).  Note:  the FITC-
stained object in the upper-right corner is background interference. 
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